Larazotide Research Applications

Larazotide, a tight-junction-regulating peptide, is a significant subject of scientific investigation, primarily due to its documented influence on intestinal barrier function. Its mechanism of action, centering on the modulation of tight junction proteins, positions it as a valuable research tool for exploring paracellular permeability pathways and epithelial barrier integrity in various preclinical and cellular models. The peptide, also known as AT-1001, has garnered attention across numerous published research studies and is the focus of several registered investigational programs, highlighting its ongoing relevance in mechanistic barrier research.

This reference page compiles information pertinent to Larazotide’s properties and research applications, strictly for laboratory and investigational purposes, to aid researchers in understanding its potential utility in diverse experimental designs. The content provided is for research reference only and does not endorse or imply any specific uses in humans, nor does it make claims regarding its safety or efficacy.

Larazotide (AT-1001): Peptide Profile and Biochemical Properties

Larazotide, also known by its research alias AT-1001, is categorized as a tight-junction peptide, a class of molecules under extensive investigation for their roles in regulating cellular paracellular permeability. As a synthetic octapeptide, its specific amino acid sequence and structural conformation are critical to its observed biological activities in research settings. The precise arrangement of its constituent amino acids confers upon Larazotide the ability to interact with specific components of the tight junction complex, thereby influencing barrier integrity and function. Understanding these intrinsic biochemical properties is fundamental for researchers aiming to accurately design and interpret studies involving this peptide. Its development as a research tool stems from a targeted approach to explore the intricate mechanisms governing epithelial and endothelial barrier dynamics.

The purity and structural integrity of Larazotide are paramount for reproducible and reliable research outcomes. Variations in synthesis or handling can lead to altered activity, emphasizing the need for rigorous quality control in its production. Researchers acquiring Larazotide for experimental purposes often scrutinize its Certificate of Analysis (CoA) to confirm its identity, purity, and concentration, ensuring that the material accurately represents the intended peptide. The molecular weight and isoelectric point are key biochemical descriptors that contribute to the peptide’s behavior in various experimental conditions, including solubility, stability, and interaction with biological matrices. Researchers must account for these properties when designing experiments, particularly those involving solution preparation, storage, and application in complex biological systems.

As a tight-junction regulating peptide, Larazotide’s biochemical profile is intrinsically linked to its functional mechanism. Peptides, in general, are highly sensitive to environmental factors such as pH, temperature, and the presence of proteases, which can affect their stability and bioavailability within research models. Larazotide’s stability profile, therefore, dictates optimal storage and handling protocols to maintain its research efficacy over time. This includes considerations for lyophilized storage, reconstitution solvents, and the duration for which reconstituted solutions remain viable for experimental use. Researchers interested in the broader context of peptide research can find more information on the characteristics and utility of such compounds by exploring what are research peptides.

The unique sequence and tight-junction modulating activity distinguish Larazotide within the broader category of research peptides. Its characterization includes detailed analyses of its chemical composition, often through techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy, which confirm its primary and secondary structures. These analyses are crucial not only for initial characterization but also for lot-to-lot consistency, which is vital for long-term research projects. The specific chemical properties of Larazotide, such as hydrophobicity and charge distribution, influence its interactions with cell membranes and intercellular proteins, providing insights into its potential cellular entry mechanisms and target binding affinities.

Key Biochemical Characteristics of Larazotide

Characteristic	Description
Peptide Class	Tight-junction peptide
Alias	AT-1001
Structure	Synthetic octapeptide
Mechanism Category	Tight-junction regulation
Primary Research Focus	Intestinal barrier research
Quality Control Importance	High purity for reproducible research

Mechanism of Action: Tight Junction Modulation in Research Contexts

The core mechanism of Larazotide (AT-1001) in research contexts revolves around its capacity to modulate tight junctions, intricate multiprotein complexes that regulate paracellular permeability in epithelial and endothelial barriers. Tight junctions are crucial for maintaining tissue homeostasis and preventing the uncontrolled passage of solutes, ions, and microorganisms. Larazotide is hypothesized to exert its effects through specific interactions with key components of the tight junction apparatus. Research has indicated that it may influence the organization and function of transmembrane proteins such as occludin and claudins, as well as cytoplasmic plaque proteins like the zona occludens (ZO) family, including ZO-1. These interactions are not fully elucidated but are central to the ongoing investigation of Larazotide’s utility as a research tool for understanding barrier dynamics.

The precise cellular and molecular pathways through which Larazotide modulates tight junctions are areas of active investigation. Studies often explore its impact on protein phosphorylation states, gene expression patterns, and the spatial distribution of tight junction proteins within cell membranes. For instance, researchers may investigate whether Larazotide directly binds to specific tight junction proteins or acts upstream by influencing signaling pathways that govern tight junction assembly and disassembly. Understanding these detailed interactions is critical for appreciating the nuanced effects observed in various experimental models of barrier function and dysfunction. Further information on the general mechanism of action for Larazotide can be found at Larazotide Mechanism of Action.

In research models, Larazotide has been observed to influence tight junction integrity, often manifesting as an alteration in transepithelial/transendothelial electrical resistance (TEER) or the flux of tracer molecules across cell monolayers. These measurable outcomes provide direct evidence of its tight junction modulating activity. The direction and magnitude of this modulation can vary depending on the specific cellular context, the presence of inflammatory stimuli, and the concentration of Larazotide used in experimental setups. Researchers rigorously control these variables to delineate the dose-dependent effects and the environmental factors that may influence its efficacy in modulating barrier function.

The investigation into Larazotide’s mechanism of action also extends to its potential influence on broader cellular processes beyond the immediate tight junction complex. Given the interconnectedness of cellular signaling, it is plausible that its effects on tight junctions could indirectly impact other cellular functions, such as cell adhesion, proliferation, or inflammatory responses. For example, by stabilizing or enhancing tight junctions, Larazotide might mitigate the entry of pro-inflammatory triggers into the submucosa, thereby indirectly influencing local immune responses in intestinal barrier research. Such potential downstream effects highlight the complexity and multi-faceted nature of Larazotide’s role as a research probe in dissecting cellular regulation.

Key Aspects of Tight Junction Modulation Research

Protein Interaction Studies: Investigation into Larazotide’s direct or indirect binding with tight junction proteins (e.g., occludin, claudins, ZO-1).
Signaling Pathway Analysis: Exploration of upstream signaling cascades (e.g., kinases, phosphatases) that are affected by Larazotide and subsequently regulate tight junction integrity.
Permeability Assays: Measurement of changes in paracellular permeability using TEER measurements, flux of fluorescent tracers, or passage of macromolecules in in vitro and in vivo models.
Morphological Assessment: Microscopic analysis (e.g., immunofluorescence, electron microscopy) to observe changes in tight junction protein localization, expression, and overall barrier ultrastructure.
Context-Dependent Effects: Studying how different cellular environments, inflammatory states, or disease models influence Larazotide’s modulatory activity on tight junctions.

Intestinal Barrier Function and Tight Junctions: A Research Perspective

The intestinal barrier represents a critical interface between the host and the external environment, playing a pivotal role in nutrient absorption while simultaneously preventing the translocation of harmful luminal contents, such as bacteria, toxins, and undigested food particles, into the systemic circulation. This sophisticated barrier is comprised of several layers, including the mucus layer, a single layer of epithelial cells, the lamina propria containing immune cells, and a rich microbiome. At the heart of the epithelial layer’s integrity are the tight junctions, which seal the paracellular space between adjacent enterocytes, meticulously regulating what passes through. From a research perspective, understanding the intricate molecular architecture and dynamic regulation of these tight junctions is fundamental to dissecting gastrointestinal physiology and pathology.

Dysfunction of the intestinal barrier, often termed “leaky gut,” is a prominent feature in the pathophysiology of numerous gastrointestinal and systemic conditions. In research models, impaired tight junction integrity leads to increased intestinal permeability, allowing luminal antigens to cross the epithelial barrier and trigger immune responses in the lamina propria. This process is intensely studied in the context of inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis, celiac disease, irritable bowel syndrome (IBS), food allergies, and even metabolic disorders and neurological conditions. Larazotide, as a tight-junction regulating peptide, serves as a valuable research tool to probe these mechanisms, enabling scientists to investigate the consequences of barrier perturbation and potential strategies for restoration.

Tight junctions are dynamic structures capable of rapid reorganization in response to various physiological and pathological stimuli, including cytokines, microbial products, nutrients, and stress. This plasticity allows the intestine to adapt to changing luminal conditions but also renders it vulnerable to disruption. Key proteins involved in tight junction formation and regulation include claudins, occludin, and junctional adhesion molecules (JAMs), which are transmembrane proteins, and the zona occludens (ZO) family of adaptor proteins (ZO-1, ZO-2, ZO-3), which link transmembrane proteins to the actin cytoskeleton. Research often focuses on how various agents, including Larazotide, influence the expression, localization, and post-translational modification of these proteins to alter barrier function.

Investigating intestinal barrier function involves a multidisciplinary approach, utilizing a range of in vitro cell culture models, explant systems, and sophisticated in vivo animal models. Researchers employ techniques to measure paracellular permeability, such as transepithelial electrical resistance (TEER) in cell monolayers, or the systemic absorption of non-metabolized probes like FITC-dextran in animal models. Complementary techniques, including immunofluorescence microscopy, Western blotting, and gene expression analysis, are used to characterize the molecular changes in tight junction proteins. The goal of such research is not only to characterize barrier breakdown but also to identify novel mechanisms and compounds, like Larazotide, that can modulate tight junction integrity, thereby offering insights into potential therapeutic targets for conditions characterized by epithelial barrier dysfunction.

The interplay between the gut microbiome and intestinal barrier function is another critical area of research. Microbial metabolites, specific bacterial species, and dysbiosis are all known to impact tight junction integrity. Larazotide’s potential to modulate tight junctions opens avenues for exploring how restoring barrier function might influence gut microbiota composition or mitigate the effects of dysbiosis in experimental models. This complex ecosystem adds another layer of intricacy to intestinal barrier research, where a comprehensive understanding requires integrating molecular, cellular, physiological, and microbiological perspectives.

Methodologies for Studying Larazotide’s Effects on Barrier Integrity

Investigating the effects of Larazotide on barrier integrity requires a diverse array of methodologies, encompassing both in vitro and in vivo approaches. The choice of methodology is dictated by the specific research question, ranging from elucidating molecular mechanisms at the cellular level to observing physiological impacts within complex organismal systems. At the forefront of in vitro studies are cell culture models, particularly those utilizing epithelial or endothelial cell lines that form polarized monolayers capable of establishing tight junctions. These models provide a controlled environment to assess direct effects on barrier properties without systemic confounding factors.

A cornerstone technique for quantifying paracellular permeability in cell monolayers is the measurement of transepithelial electrical resistance (TEER). By applying a low-level alternating current across a cell monolayer grown on a permeable support, changes in TEER values directly correlate with the tightness of the junctions. An increase in TEER typically indicates enhanced barrier integrity, while a decrease suggests compromise. This is often complemented by tracer flux assays, where the passage of inert, non-metabolized molecules of varying sizes (e.g., fluorescently labeled dextrans or mannitol) across the monolayer is quantified. Larazotide’s impact on these parameters provides quantifiable evidence of its tight junction modulating activity.

Beyond functional assays, molecular and morphological techniques are crucial for unraveling the mechanisms underlying Larazotide’s effects. Immunofluorescence microscopy is widely employed to visualize the localization and distribution of specific tight junction proteins (e.g., ZO-1, occludin, various claudins) within cell-cell contacts. Changes in the continuity, intensity, or cellular location of these proteins after Larazotide treatment can provide insights into its mechanism. Western blotting and quantitative PCR (qPCR) are used to assess the expression levels of tight junction proteins and associated signaling molecules, allowing researchers to determine if Larazotide influences protein synthesis or degradation pathways, or gene transcription.

For a more comprehensive understanding of Larazotide’s physiological relevance, in vivo animal models are indispensable. These models allow for the study of complex interactions between the gut barrier, immune system, nervous system, and microbiome. Common techniques include measuring intestinal permeability using orally administered fluorescent probes (e.g., FITC-dextran) followed by quantification in blood plasma. Additionally, tissue samples from treated animals can be subjected to histological analysis, immunohistochemistry for tight junction proteins, and electron microscopy to examine ultrastructural changes in the epithelial barrier. Advanced methodologies like transcriptomics and proteomics can also be applied to identify global changes in gene and protein expression in response to Larazotide administration in animal models, offering a broader view of its biological impact.

Common Methodologies for Studying Barrier Integrity with Larazotide

In Vitro Cell Culture Models:
- Transepithelial Electrical Resistance (TEER) Measurement: Quantifies electrical resistance across epithelial/endothelial monolayers as an indicator of tight junction integrity.
- Tracer Flux Assays: Measures the paracellular passage of inert molecules (e.g., FITC-dextran, mannitol) across cell monolayers.
- Immunofluorescence Staining: Visualizes the localization and distribution of tight junction proteins (e.g., ZO-1, occludin, claudins) at cell-cell contacts.
- Western Blotting & qPCR: Analyzes the expression levels of tight junction proteins and related signaling molecules at the protein and mRNA level.
In Vivo Animal Models:
- Oral Permeability Assays: Administration of non-digestible probes (e.g., FITC-dextran) and measurement of their systemic absorption to assess intestinal permeability.
- Histology & Immunohistochemistry: Examination of tissue morphology and tight junction protein expression/localization in tissue sections.
- Electron Microscopy: Provides ultrastructural details of tight junctions and the overall epithelial architecture.
- Omics Approaches: Transcriptomics, proteomics, and metabolomics to identify global molecular changes in response to Larazotide treatment.

Preclinical Research Applications of Larazotide

Larazotide’s unique mechanism as a tight-junction regulating peptide has positioned it as a compelling subject for extensive preclinical research across various disciplines, primarily focused on intestinal barrier function. The numerous PubMed publications and several ClinicalTrials.gov registered studies underscore its significant research interest. In preclinical models, Larazotide is predominantly investigated for its potential to modulate epithelial barrier integrity, a critical factor in the pathogenesis of numerous conditions. These applications span from understanding fundamental biological processes to exploring its utility in experimental models of disease where barrier dysfunction is a hallmark.

One of the primary preclinical research applications of Larazotide is in models of inflammatory conditions affecting mucosal barriers. For instance, in experimental models designed to mimic inflammatory bowel diseases (IBD), researchers have explored whether Larazotide can attenuate inflammation by reinforcing the intestinal barrier, thereby limiting the translocation of pro-inflammatory luminal contents. By stabilizing tight junctions, Larazotide may reduce antigen exposure to the submucosal immune system, potentially mitigating the initiation or perpetuation of inflammatory cascades. This line of inquiry is crucial for identifying novel strategies to manage intestinal inflammation.

Beyond inflammatory conditions, Larazotide is also being investigated in models of celiac disease. In this autoimmune disorder, gluten peptides trigger an immune response that damages the small intestinal lining, leading to increased permeability. Preclinical studies have explored Larazotide’s capacity to prevent or reverse gluten-induced tight junction disruption, offering insights into alternative approaches to manage gluten-related enteropathy. This involves studying its effects on epithelial integrity in the presence of gluten challenges, assessing permeability markers, and evaluating histological changes in intestinal tissue.

Furthermore, Larazotide has found application in research exploring drug delivery systems and the absorption of macromolecules. By transiently modulating tight junction permeability, researchers investigate whether Larazotide can enhance the paracellular transport of co-administered therapeutic agents that otherwise exhibit poor oral bioavailability. This research avenue is significant for understanding how to overcome biological barriers to improve drug efficacy. Additionally, its role in preventing the systemic consequences of increased intestinal permeability, such as bacterial translocation in sepsis models or metabolic endotoxemia in obesity research, represents another important area of preclinical investigation.

Examples of Preclinical Research Areas for Larazotide

Inflammatory Bowel Disease (IBD) Models: Investigating its potential to reduce inflammation by enhancing intestinal barrier integrity in chemically induced or genetically predisposed models of colitis.
Celiac Disease Models: Studying its ability to counteract gluten-induced tight junction disruption and subsequent intestinal permeability in experimental settings.
Sepsis and Endotoxemia Models: Exploring its role in preventing bacterial translocation and systemic inflammation arising from a compromised gut barrier.
Drug Delivery Enhancement: Researching its capacity to transiently open tight junctions to improve paracellular absorption of co-administered large molecules or poorly permeable drugs.
Nutrient Absorption Studies: Examining its influence on the absorption of specific nutrients or micronutrients by modulating the paracellular pathway.

Investigating the Role of Larazotide in Models of Barrier Dysfunction

The investigation of Larazotide’s role in models of barrier dysfunction is a cornerstone of current endocrinology and gastrointestinal research. Barrier dysfunction, often characterized by increased permeability of epithelial or endothelial layers, contributes to the pathophysiology of a vast array of diseases beyond the gastrointestinal tract, including respiratory, renal, and neurological conditions. Larazotide, as a tight-junction regulating peptide, offers a unique tool to experimentally manipulate barrier integrity, thereby allowing researchers to dissect the causal relationship between barrier compromise and disease progression in a controlled environment.

One prominent area of investigation involves models of inflammatory bowel disease (IBD), where increased intestinal permeability is a well-established feature. In research settings, animal models such as dextran sodium sulfate (DSS)-induced colitis or TNBS-induced colitis are widely used to mimic human IBD. Researchers administer Larazotide in these models to determine if it can mitigate the inflammatory response by restoring or preserving tight junction function. Studies focus on endpoints such as disease activity index, colonic tissue damage, inflammatory cytokine levels, and, crucially, markers of intestinal permeability like FITC-dextran flux, to assess the peptide’s effects on the dysfunctional barrier.

Another significant research application is in models of celiac disease. Here, exposure to gluten in genetically predisposed individuals leads to enteropathy and increased intestinal permeability. In vitro models using human intestinal epithelial cell lines (e.g., Caco-2) or intestinal organoids, often challenged with gliadin peptides, are employed to simulate the cellular effects of gluten. Larazotide’s ability to prevent gliadin-induced reduction in TEER or enhance the expression/localization of tight junction proteins in these models provides critical insights into its potential for counteracting specific triggers of barrier dysfunction. In vivo models of celiac-like enteropathy also utilize Larazotide to observe its impact on villous atrophy and inflammatory markers.

Beyond chronic inflammatory conditions, Larazotide is being explored in acute barrier dysfunction models, such as those related to sepsis, ischemia-reperfusion injury, or drug-induced enteropathy (e.g., NSAID-induced damage). In these scenarios, rapid and severe barrier breakdown can lead to systemic complications. Research aims to understand if Larazotide can prevent or reduce the severity of these acute permeability changes, potentially limiting bacterial translocation, endotoxemia, and multi-organ dysfunction in experimental setups. The kinetics of Larazotide’s action in these rapid-onset models are particularly relevant for understanding its physiological impact.

Furthermore, researchers are exploring the role of Larazotide in models where barrier dysfunction is secondary to other insults, such as stress, changes in the gut microbiome, or exposure to specific environmental toxins. For example, some studies investigate whether Larazotide can modulate gut permeability in animal models of psychological stress, linking psychological factors to gut barrier integrity. By providing a tool to directly influence tight junctions, Larazotide enables the intricate study of these complex multifactorial conditions, offering a deeper understanding of the mechanisms linking barrier health to overall physiological well-being in research animals.

Emerging Research Avenues and Future Directions for Larazotide Studies

The research landscape surrounding Larazotide (AT-1001) is continuously evolving, with numerous PubMed publications and several ClinicalTrials.gov registered studies pointing towards a dynamic future for its investigation. Beyond its established role in intestinal barrier research, emerging research avenues are exploring its utility in modulating other epithelial and endothelial barriers throughout the body. The fundamental mechanism of tight junction regulation is not exclusive to the gut; similar barrier structures exist in the lungs, kidneys, blood-brain barrier, and skin, suggesting potential broader applications for Larazotide as a research tool.

One significant future direction involves investigating Larazotide’s effects on extra-intestinal barriers. For example, in models of acute lung injury or asthma, researchers could explore whether Larazotide influences alveolar-capillary barrier permeability, potentially impacting inflammation or fluid accumulation. Similarly, studies could extend to the blood-brain barrier (BBB), where tight junction dysfunction is implicated in neuroinflammatory and neurodegenerative conditions. While challenging due to delivery, in vitro BBB models or specific animal models might offer initial insights into Larazotide’s ability to modulate this critical barrier, contributing to the understanding of central nervous system physiology

Frequently Asked Questions

What is Larazotide primarily studied for in research?

Larazotide (AT-1001) is primarily studied in research for its role as a tight-junction-regulating peptide, particularly in the context of intestinal-barrier function and paracellular permeability.

Are there aliases for Larazotide in research literature?

Yes, Larazotide is also commonly referred to by its investigational alias, AT-1001, across various research publications and study registrations.

How does Larazotide’s mechanism of action relate to cellular research?

Larazotide’s mechanism of action involves the modulation of tight junctions, which are critical protein complexes that regulate paracellular permeability between epithelial cells. In cellular research, this mechanism is investigated to understand how the peptide might influence barrier integrity and transport across cell layers.

How many published studies are there involving Larazotide?

There are numerous published research studies indexed on PubMed that explore the properties and effects of Larazotide, underscoring its significant presence in barrier function research.

Has Larazotide been investigated in registered studies?

Yes, Larazotide has been the subject of several registered studies on platforms such as ClinicalTrials.gov, indicating ongoing investigational programs exploring its potential research applications.

What class of compounds does Larazotide belong to?

Larazotide is classified as a tight-junction peptide, a category of compounds that can interact with and potentially modulate the structural and functional aspects of tight junctions.

In what research models might Larazotide be employed?

Larazotide might be employed in various *in vitro* models, such as Caco-2 or T84 cell monolayers, and *in vivo* animal models to investigate its effects on intestinal barrier integrity, permeability, and related physiological responses.

Is this information about Larazotide for human use?

No, the information provided on Larazotide is strictly for research use only. It is intended to serve as a reference for researchers and does not imply or endorse any human dosing, therapeutic applications, or claims regarding safety or efficacy in humans.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.